Several vaccines company performance in 2017 is growing rapidly

wisdom fly companies such as biological, KTS, longevity biological growth significantly. Among them, 12 times fly biological net profit jumped.

wisdom fly, according to the biological performance express 2017 operating income of 1.343 billion yuan, up 201.06% from a year earlier. Net income of 432 million yuan, up 1229.25% from a year earlier. Flying creatures for a sharp rise in performance is due, intelligence, said during the reporting period, the 2016 & other; 3 & middot; 18 the vaccine industry events throughout the &; The industry policy change is gradually eliminate the uncertainty factors, such as industry ground step by step implementation of the New Deal, industry environment, further standardize, 2 kinds of vaccine company products and agent products promotion and sales work resumption.

in addition, KTS biological and immortality business income is 1.164 billion yuan and 1.553 billion yuan respectively, 2017, year-on-year growth of 110.95% and 52.60%, respectively; Net profit of 217 million yuan and 565 million yuan respectively, year-on-year growth of 152.32% and 152.32% respectively.

Watson creatures into huge losses. However, its contribution by independent vaccine products net profit growth is obvious. Announcement shows that Watson biological independent vaccine products in 2017 sales revenue of 515 million yuan, year-on-year increase of 292 million yuan, up by 130.99%; Net profit year-on-year increase of 80.6002 million yuan, an increase of 625.20%.

blockbuster varieties listed will take turns

even if encounter performance suddenly turn hostile, Watson creature’s share price has not recovered. With large securities believes that the first blockbuster 13 pneumococcal conjugate vaccine in the market at the end of 2018 to early 2019, Watson biological results will usher in rapid growth.

according to the China securities journal reporter know, 13 pneumococcal vaccine for infants and young children to prevent invasive pneumococcal disease in our country has important clinical value. Watson biology in the research of the 13 pneumococcal vaccines for the world’s second home. Combined with Pfizer in 13 pneumococcal conjugate vaccine in 2016 made a $5.7 billion global sales of individual products, several brokerages think Watson biological 13 pneumococcal vaccine after future will exceed market expectations, bring huge performance increment for the company.

in addition, Watson biological cervical cancer prevention of bivalent HPV vaccine and therapy of breast cancer herceptin and arthritis, such as blockbuster drugs were in clinical stage III stage. Insiders predict time to market in 2020 or so, the future any varieties listed, the company’s performance will be rapid growth.

wisdom fly in biology, with recent high-profile MSD HPV vaccine (cervical cancer vaccine) and 4 price pentavalent rotavirus vaccine (vaccine) to prevent rotavirus enteritis sole agency in China. According to China’s food and drug verification research institute, according to data from Merck 4 price HPV vaccine in January 2018, the number of approved sign is about 600000. In addition, the price of five rotavirus vaccines are now included in the priority review, the industry is expected in 2018 approved by the public.

in addition to the sole agent of blockbuster drugs, in the research of flying creature varieties rich in reserves. In its diagnosis and prevention of tuberculosis has many varieties in development completed clinical Ⅲ period, mainly including preventive micro card, EC diagnostic reagents, etc., the industry is expected to go on sale in early 2019. At the same time, the think tank flying creature independent research and development of freeze-dried vaccine Hib (haemophilus influenzae type b vaccine), 15 pneumococcal vaccines and freeze-drying with rabies vaccine and other products also have obtained the approval documents of clinical.

multiple varieties of conde creatures will be listed in succession, or performance of the listed companies have a significant impact in the future. Among them, 23 pneumococcal vaccine and the third generation of wild dog vaccine & ndash; & ndash; Freeze-dried people with rabies vaccine are listed on site inspection before stage at present. Southwest securities is expected, the above two varieties will be listed in 2018, is expected to net profit contribution of about 100 million yuan and 500 million yuan respectively. In addition, the 13 of conde biological pneumococcal vaccine is currently in clinical Ⅲ period. According to southwest securities, expects conde biological 13 pneumococcal vaccine will be listed in 2020, contributing to the listed company net profit or exceeds 1 billion yuan. (internship reporter zhang bin)

Leave a Reply

Your email address will not be published. Required fields are marked *